

Clarke, Modet & C^o

COLOMBIA

P-3530

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 12-186907- -00005-0000

Fecha: 2014-01-17 15:24:00 Dep. 2020 DIR.NUEVASCR
Tra. 11 PATENTEIYII Eve: 379 FASENACIONALII
Act. 523 RESPUESTA Folios: 21

SUPERINTENDENCIA DE INDUSTRIAL
DIVISION DE NUEVAS CREACIONES
E. S. D.

Re: Expediente No. 12.186.907

Solicitud de patente a nombre de **GW PHARMA LIMITED Y
OTSUKA PHARMACEUTICAL CO. LIMITED**

Yo, SILVANA MARIA LOPEZ DIAZ identificada como aparece al pie de mi firma, domiciliada en la Carrera 11 No. 86-53, piso 6, obrando como apoderada sustituta de acuerdo con la sustitución adjunta de las sociedades GW PHARMA LIMITED y OTSUKA PHARMACEUTICAL CO. LIMITED, domiciliados en Reino Unido y Japón, respectivamente, solicitantes de la patente de la referencia, en respuesta al oficio No. 19492 notificado por fijación en lista el 22 de octubre de 2013, relacionado con concepto técnico de fondo, me permito manifestar:

1. Con fundamento en la facultad que confiere el artículo 34 de la Decisión 486 al solicitante para modificar la solicitud de patente en cualquier momento del trámite, presento junto con este memorial nuevo capítulo reivindicatorio, el cual consta de 16 reivindicaciones y reemplaza completamente el capítulo presentado anteriormente. En el nuevo capítulo reivindicatorio se realizaron las siguientes modificaciones:
 - 1.1 Como primera medida, se modificó todo el capítulo reivindicatorio con el fin de indicar la invención reclamada como una formulación y un extracto de planta de cannabis, sin hacer referencia a los usos que corresponden a un objeto no patentable.
 - 1.2 Adicionalmente, se eliminaron del presente capítulo reivindicatorio todos los términos que puedan ser considerados por el examinador como ambiguos e imprecisos, con el fin de permitir la identificación de las diferencias técnicas de la presente invención con el estado de la técnica.

En cuanto a estas modificaciones, me permito decir que las mismas no amplían de ninguna manera la materia objeto de la presente solicitud y se realizaron con el ánimo de superar las objeciones de claridad, novedad y nivel inventivo planteadas por el examinador en su concepto técnico.

P-3530

En cuanto al número de reivindicaciones, atentamente nos permitimos decir que no se adjunta tasa por reivindicaciones adicionales, toda vez que el nuevo capítulo reivindicatorio tiene menos cláusulas que el originalmente presentado y en esencia es el mismo objeto pero ajustado a las normas de patentabilidad en Colombia.

2. Claridad de la solicitud

En cuanto al título de la solicitud, es deseo del solicitante indicar el nuevo título "FORMULACIÓN FARMACEUTICA Y EXTRACTO DE PLANTA DE CANABIS QUE COMPRENDEN CANABIDIVARINA".

Respecto a las objeciones de claridad, el solicitante manifiesta que mediante la presentación del nuevo capítulo reivindicatorio quedan subsanadas la totalidad de las objeciones, de modo tal que las nuevas reivindicaciones proporcionan claridad y concisión a la invención descrita, siguiendo las recomendaciones realizadas por el examinador en su concepto técnico.

Como primera medida, es deseo del solicitante indicar que el nuevo capítulo reivindicatorio no contiene reivindicaciones de uso, lo cual corresponde a una materia objeto no patentable en Colombia. Por el contrario, el nuevo capítulo reivindicatorio define una formulación que comprende una cantidad de canabidivirina (CBDV) y un extracto de planta de cannabis que comprende un componente que contiene fitocabanoide y un componente que no contiene fitocabanoide.

Adicionalmente, siguiendo las recomendaciones del examinador, la expresión "*un mecanismo de acción que actúa a través de*" incluida en las antiguas reivindicaciones 11 y 12 fueron eliminadas en el nuevo capítulo reivindicatorio. Además, el término "*por lo menos*" fue eliminado de las reivindicaciones.

Por otra parte, tanto la formulación como el extracto de planta de cannabis reclamados en la presente solicitud fueron definidos de una forma clara y específica, incluyendo los componentes y las proporciones de estos en la formulación y en el extracto, respectivamente.

En cuanto los ejemplos incluidos en el capítulo descriptivo de la presente solicitud, es deseo del solicitante indicar al examinador que dichos ejemplos contienen información que demuestran la efectividad de los cannabinoides a diferentes dosis, lo que claramente es una evidencia de la efectividad sinérgica que logra la formulación de la presente invención en el alivio de las convulsiones causadas por la epilepsia.

En consecuencia, nos permitimos informar que las nuevas reivindicaciones 1 a 16

se ajustan a las disposiciones del artículo 30 de la Decisión 486.

3. Novedad

El examinador establece en su concepto técnico que la materia contenida en las antiguas reivindicaciones 1 a 12 de la presente solicitud carece de novedad a la luz del documento WO2004016246 (D1).

En este sentido, se encuentra que el artículo 16 de la Decisión 486/00 determina que *“una invención es nueva cuando no está comprendida en el estado de la técnica. El estado de la técnica comprenderá todo lo que haya sido accesible al público, por una descripción escrita u oral, por una utilización o cualquier otro medio antes de la fecha de presentación de la solicitud de patente o, en su caso, de la prioridad reconocida”*.

Teniendo en cuenta lo anterior, es deseo del solicitante manifestar que difiere de la opinión del examinador, toda vez que el documento D1 no describe una formulación que comprende una cantidad de CBDV donde el CBDV puede estar en cuatro distintas formas: i) presente en forma pura o aislada, ii) solo, iii) ausente de tetrahidrocanabidivarina (THCV), o iv) junto con THCV sin ser una formulación que comprende una relación CBDV:THCV de 95:5. Adicionalmente, el documento D1 no describe un extracto de planta de cannabis que comprende un componente que contiene fitocanabinoide que tiene 50-100% (p/p) del extracto de planta de cannabis, con un fitocanabinoide principal CBDV en una cantidad de 40-100% (p/p) del extracto de planta de cannabis, con un fitocanabinoide secundario canabidiol (CBD) en una cantidad de 10-100% (p/p) del extracto de planta de cannabis, y con una cantidad pequeña de cannabinoides de 0-5% (p/p) del extracto de planta de cannabis, y un componente que no contiene fitocanabinoide que contiene monoterpenos y sesquiterpenos.

Las características anteriores son definidas en forma específica en la presente solicitud con relación a la descripción genérica incluida en D1, de tal forma que las reivindicaciones de la presente invención representan una selección novedosa dentro las formulaciones farmacéuticas y extractos de cannabis incluidas en D1. Por otra parte, dicha selección de la presente invención está intencionalmente dirigida a la obtención de una formulación utilizada para aliviar las convulsiones causadas por la epilepsia.

Al realizar un análisis detallado del documento D1, se encuentra que la enseñanza más relevante contenida en dicho documento es la contenida en la tabla 2. En esta, es sugerido que una relación THC:CBD menor que 5:95 es la forma más adecuada para el tratamiento de epilepsia. Adicionalmente, en dicho documento se indica que la relación THC:CBD puede ser sustituida por la relación THCV:CBDV. Esto se indica con base en una suposición de la época, que consiste en que las similitudes estructurales entre THC y THCV, y CBD y CBDV

Clarke, Modet & C^o

COLOMBIA

darían lugar a una actividad terapéutica similar. Sin embargo, esta similitud fue subsecuentemente encontrada como inválida ya que el análogo propilo de THC, es decir el THCV, tiene efectos opuestos, por lo menos en lo que respecta al receptor CB1 (Thomas et al., 2005). Copia de este documento se encuentra adjunta como anexo al presente memorial.

De acuerdo a esto, en la fecha de presentación de la presente solicitud, la persona del oficio versada en la técnica no hubiera considerado que los análogos de propilo, incluyendo CBDV, se comportarían de manera similar al canabinoide pentilo más común (CBD).

Teniendo en cuenta lo anterior, se demuestra que las enseñanzas de la tabla 2 del documento D1, no anticipan de ninguna manera una formulación que comprende una cantidad terapéuticamente efectiva de CBDV.

De esta forma, es claro para un experto en la materia que las invenciones definidas en el estado del arte y la presente solicitud, son completamente diferentes y por lo tanto, son novedosas una con respecto a la otra.

En este sentido, la presente solicitud tal y como se encuentra definida en las nuevas reivindicaciones 1 a 16, tiene diferencias con el estado del arte y, por tanto, debe ser considerada como novedosa según las disposiciones del artículo 16 de la Decisión 486.

4. Nivel Inventivo

El examinador establece en su concepto técnico que la antigua reivindicación 13 de la presente solicitud, que corresponde parcialmente a la nueva reivindicación 10, carece de nivel inventivo a la luz de los documentos WO02064109 (D2) y WO03099302 (D3).

De este modo, me permito indicar que el artículo 18 de la Decisión 486 establece que *“Se considerará que una invención tiene nivel inventivo, si para una persona del oficio normalmente versada en la materia técnica correspondiente, esa invención no hubiese resultado obvia ni se hubiese derivado de manera evidente del estado de la técnica”*.

Lo anterior significa que el análisis de nivel inventivo **NO** es una comparación de los objetos de las anterioridades y la solicitud en estudio. El análisis de nivel inventivo **debe demostrar** la obviedad de la invención y establecer cómo ésta no contiene un salto cualitativo, que demuestre su altura inventiva, teniendo en cuenta que se hace **necesario demostrar** que la invención analizada carece de nivel inventivo y hubiese sido obvia para una persona versada en la materia.

Considerando la anterior definición, es deseo del solicitante indicar que la nueva

Clarke, Modet & C^o

COLOMBIA

reivindicación 10 describe un extracto de planta de cannabis que comprende “*un componente que contiene fitocanabinoide y un componente que no contiene fitocanabinoide, en donde el componente que contiene fitocanabinoide comprende de 50-100% (p/p) del extracto de planta de cannabis y contiene como un fitocanabinoide principal CBDV, presente en una cantidad de 40-100% (p/p) del extracto de planta de cannabis, y como un canabinoide secundario cannabidiol (CBD), presente en una cantidad de 10-100% (p/p) del extracto de planta de cannabis, con una cantidad menor de canabinoides de 0-5% (p/p) del extracto de planta de cannabis, y en donde el componente que no contiene fitocanabinoide comprende monoterpenos y sesquiterpenos*”.

Así, es deseo del solicitante indicar que no es posible que un experto en la materia derivara la presente invención de una forma obvia, ya que todas las características técnicas incluidas en la nueva reivindicación 10, no son reveladas ni sugeridas en forma individual en los documentos D2 y D3, y por lo tanto tampoco en la combinación de estos.

La información incluida en el documento D2, particularmente en la tabla 4 (página 33), indica la misma suposición indicada anteriormente en el análisis del documento D1. Por lo tanto, en la fecha de presentación de la presente aplicación, la persona del oficio medianamente versada en la técnica no hubiera considerado que el CBDV se comportaría de manera similar al CBD.

Adicionalmente, es deseo del solicitante resaltar que el documento D3 citado por el examinador se refiere a una composición a base de terpeno, lo cual se aleja totalmente del campo de conocimiento de la invención, que corresponde a una formulación farmacéutica y un extracto de cannabis enfocada en el alivio de las convulsiones causadas por la epilepsia. Así, el documento D3, no puede ser tenido en cuenta como anterioridad pertinente en el análisis de patentabilidad de la presente invención.

De esta forma, las nuevas reivindicaciones 1 a 16 cumplen con el requisito de nivel inventivo, tal como se define en el artículo 18 de la Decisión 486 y como se explica detalladamente en el Manual Andino y la Guía para Examinadores de la Superintendencia de Industria y Comercio.

Habiendo atendido cabalmente las objeciones presentadas por ese despacho, atentamente solicitamos se conceda el privilegio de patente de invención a la solicitud en estudio o si el señor examinador considera que subsisten razones para objetar la presente invención, rogamos expedir otro examen de fondo con los debidos motivos y razones que sustenten su objeción con el fin de que nuestro mandante tenga la posibilidad de exponer sus argumentos con base en la interpretación de los artículos 45 de la Decisión 486 -el cual otorga la facultad al examinador para emitir los exámenes de fondo-, 35 y 59 del Código Contencioso Administrativo que señala que: “*habiéndose dado oportunidad a los interesados para*

Clarke, Modet & Cº

COLOMBIA

expresar sus opiniones, y con base en las pruebas e informes disponibles, se tomará la decisión que será motivada al menos en forma sumaria si afecta a particulares” y “(..) deberá proferirse la decisión definitiva. Esta se motivará en sus aspectos de hecho y de derecho, y en los de conveniencia si es el caso”, respectivamente (El subrayado es nuestro).

En consecuencia, solicitamos a ese despacho pronunciarse en relación con todos los argumentos presentados en este memorial dando estricta aplicación al principio del debido proceso consagrado en el artículo 29 de la Constitución Nacional

Señor Superintendente,



SILVANA MARIA LÓPEZ DÍAZ

C.C. 22.468.787 de Barranquilla

T.P 147463 del CSJ

notificaciones@clarkemodet.com.co

Clarke, Modet & C^o

COLOMBIA

ANEXOS

- Thomas A., Stevenson LA., Wease K.N., Price M.R, Baillie G., Ross, R.A., Pertwee RG. (2005) Evidence that the plant cannabinoid Δ^9 -tetrahydrocannabivarin is a cannabinoid CB₁ and CB₂ receptor antagonist. *British Journal of Pharmacology* 146, 917-926.

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
DIVISION DE NUEVAS CREACIONES

E.

S.

D.

Re: Expediente No. 12.186.907

Solicitud de patente a nombre de **GW PHARMA LIMITED Y OTSUKA
PHARMACEUTICAL CO. LIMITED**


Yo, **DILIA RODRÍGUEZ D' ALEMAN**, identificada como aparece al pie de mi firma, domiciliada en Bogotá, Colombia, atentamente informo a usted que sustituyo el poder con que obro a la doctora **SILVANA MARÍA LÓPEZ DÍAZ**, domiciliada en Bogotá, identificada con la Cédula de Ciudadanía No. 22.468.787 y portadora de la tarjeta profesional No. 147.463 del CSJ, con las mismas facultades con que me fueron conferidas para este caso.

Señor Superintendente,



DILIA RODRIGUEZ D' ALEMAN
C.C. 41.654.882 de Bogotá
TP 20824 CSJ


Acepto sustitución



SILVANA MARÍA LÓPEZ DÍAZ
C.C. No. 22.468.787
TP 147463 CSJ

PRESENTACION PERSONAL
El anterior escrito fue presentado ante el
NOTARIO ONCE DEL CIRCULO DE BOGOTA, D.C.
personalmente por DINA RODRIGUEZ
DINA RODRIGUEZ
quien exhibió la c.c. 41654882 2065 RA
y Tarjeta Profesional No. 00324 C.S. **31 OCT 2013**
Fecha [Signature]

Guillermo Chavez Cristancho
NOTARIO


REPUBLICA DE COLOMBIA
Guillermo Chavez Cristancho
NOTARIO DEL CIRCULO DE BOGOTA D.C.

REIVINDICACIONES

1. Una formulación que comprende una cantidad terapéuticamente efectiva de canabidivarina (CBDV) y un excipiente farmacéuticamente aceptable, en donde el CBDV esta:

- i. presente en forma pura o aislada; o
- ii. solo; o
- iii. ausente de tetrahidrocanabidivarina (THCV); o
- iv. junto con tetrahidrocanabidivarina (THCV) pero no incluye una formulación que comprende CBDV y THCV en una relación de 95:5 (CBDV:THCV).

2. La formulación de acuerdo a la reivindicación 1, en donde el CBDV se encuentra presente en una dosis humana equivalente de 8.11 mg/kg.

3. La formulación de acuerdo a cualquiera de las reivindicaciones anteriores, en donde el CBDV se prepara con otro fitocanabinoide terapéuticamente efectivo.

4. La formulación de acuerdo a la reivindicación 3, en donde el otro fitocanabinoide terapéuticamente efectivo es cannabidiol (CBD).

5. La formulación de acuerdo a la reivindicación 1, en donde el CBDV está en forma aislada.

6. La formulación de acuerdo a las reivindicaciones 1 a 5, en donde el CBDV está en la forma de una sustancia de fármaco botánica en la que el CBDV es el canabinoide principal.

7. La formulación de acuerdo a cualquiera de las reivindicaciones anteriores, en donde la formulación además comprende un fármaco antiepiléptico estándar, en donde el fármaco antiepiléptico estándar actúa a través de canales de sodio o calcio, o mejora la inhibición GABAérgica, como se ejemplifica por el fenobarbital.

8. La formulación de acuerdo a la reivindicación 7, en donde el fármaco antiepiléptico estándar actúa a través de canales de sodio o calcio, y:

- modifica corrientes de calcio neuronales transitorias o de bajo umbral, como se ejemplifica por etosuximida; o
- reduce potenciales de descarga neuronal de alta frecuencia y acción dependiente de sodio y adicionalmente puede mejorar los efectos GABA, como se ejemplifica por valproato.

9. La formulación de acuerdo a cualquiera de las reivindicaciones anteriores, en donde la formulación no exhibe efectos secundarios motrices notables.

10

10. Un extracto de planta de cannabis que comprende un componente que contiene fitocanabinoide y un componente que no contiene fitocanabinoide, en donde el componente que contiene fitocanabinoide comprende de 50-100% (p/p) del extracto de planta de cannabis y contiene como un fitocanabinoide principal CBDV, presente en una cantidad de 40-100% (p/p) del extracto de planta de cannabis, y como un canabinoide secundario cannabidiol (CBD), presente en una cantidad de 10-100% (p/p) del extracto de planta de cannabis, con una cantidad menor de cannabinoides de 0-5% (p/p) del extracto de planta de cannabis, y en donde el componente que no contiene fitocanabinoide comprende monoterpenos y sesquiterpenos.

20

11. El extracto de planta de cannabis de acuerdo a la reivindicación 10, en donde el extracto de planta de cannabis además comprende THCV.

25

12. El extracto de planta de cannabis de acuerdo a cualquiera de las reivindicaciones 10 a 11, en donde el componente que contiene fitocanabinoide comprende 64-78% (p/p) del extracto de planta de cannabis.

30

13. El extracto de planta de cannabis de acuerdo a las reivindicaciones 10 a 12; que comprende 52-64% (p/p) CBDV del componente que contiene fitocanabinoide.

35

14. El extracto de planta de cannabis de acuerdo a las reivindicaciones 10 a 13, que comprende 22-27% (p/p) CBD del componente que contiene fitocanabinoide.

11

15. El extracto de planta de cannabis de acuerdo a las reivindicaciones 10 a 14, que comprende 3.9-4.7% (p/p) de THCV del componente que contiene fitocanabinoide.

5 16. El extracto de planta de cannabis de acuerdo a las reivindicaciones 10 a 15, que no exhibe efectores secundarios motrices notables.

11

Evidence that the plant cannabinoid Δ^9 -tetrahydrocannabivarin is a cannabinoid CB₁ and CB₂ receptor antagonist

¹Adèle Thomas, ¹Lesley A. Stevenson, ¹Kerrie N. Wease, ¹Martin R. Price, ¹Gemma Baillie, ¹Ruth A. Ross & ^{*,1}Roger G. Pertwee

¹School of Medical Sciences, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD

1 Δ^9 -tetrahydrocannabivarin (THCV) displaced [³H]CP55940 from specific binding sites on mouse brain and CHO-hCB₂ cell membranes (K_i = 75.4 and 62.8 nM, respectively).

2 THCV (1 μ M) also antagonized CP55940-induced stimulation of [³⁵S]GTP γ S binding to these membranes (apparent K_B = 93.1 and 10.1 nM, respectively).

3 In the mouse vas deferens, the ability of Δ^9 -tetrahydrocannabinol (THC) to inhibit electrically evoked contractions was antagonized by THCV, its apparent K_B -value (96.7 nM) approximating the apparent K_B -values for its antagonism of CP55940- and *R*-(+)-WIN55212-induced stimulation of [³⁵S]GTP γ S binding to mouse brain membranes.

4 THCV also antagonized *R*-(+)-WIN55212, anandamide, methanandamide and CP55940 in the vas deferens, but with lower apparent K_B -values (1.5, 1.2, 4.6 and 10.3 nM, respectively).

5 THCV (100 nM) did not oppose clonidine, capsaicin or (–)-7-hydroxy-cannabidiol-dimethylheptyl-induced inhibition of electrically evoked contractions of the vas deferens.

6 Contractile responses of the vas deferens to phenylephrine hydrochloride or β , γ -methylene-ATP were not reduced by 1 μ M THCV or *R*-(+)-WIN55212, suggesting that THCV interacts with *R*-(+)-WIN55212 at prejunctional sites.

7 At 32 μ M, THCV did reduce contractile responses to phenylephrine hydrochloride and β , γ -methylene-ATP, and above 3 μ M it inhibited electrically evoked contractions of the vas deferens in an SR141716A-independent manner.

8 In conclusion, THCV behaves as a competitive CB₁ and CB₂ receptor antagonist. In the vas deferens, it antagonized several cannabinoids more potently than THC and was also more potent against CP55940 and *R*-(+)-WIN55212 in this tissue than in brain membranes. The bases of these agonist- and tissue-dependent effects remain to be established.

British Journal of Pharmacology (2005) 146, 917–926. doi:10.1038/sj.bjp.0706414; published online 3 October 2005

Keywords: Δ^9 -Tetrahydrocannabivarin; Δ^9 -tetrahydrocannabinol; *R*-(+)-WIN55212; anandamide; methanandamide; CP55940; cannabinoids; mouse vas deferens; CB₁ receptor antagonist; CB₂ receptor antagonist

Abbreviations: anandamide, arachidonoyl ethanolamide; BSA, bovine serum albumin; capsaicin, 3-methoxy-4-hydroxy-benzyl-8-methyl-6-nonenamide; CHO, Chinese hamster ovary; CP55940, (–)-*cis*-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-*trans*-4-(3-hydroxypropyl)cyclohexanol; DMSO, dimethyl sulphoxide; GDP, guanosine 5'-diphosphate; GTP γ S, guanosine 5'-*O*-(3-thiotriphosphate); methanandamide, *R*-(+)-arachidonoyl-1'-hydroxy-2'-propylamide; β , γ -methylene-ATP, β , γ -methyleneadenosine 5'-triphosphate; *R*-(+)-WIN55212, (*R*)-(–)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone; SR141716A, *N*-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazole-3-carboxamide hydrochloride; SR144528, *N*-[(1*S*)-endo-1,3,3-trimethyl bicyclo [2.2.1] heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide; THC, Δ^9 -tetrahydrocannabinol; THCV, Δ^9 -tetrahydrocannabivarin

Introduction

Cannabis sativa is the natural source of a set of at least 66 oxygen-containing aromatic hydrocarbon compounds that are known collectively as phytocannabinoids (reviewed in ElSohly, 2002). This study focused on a little-investigated phytocannabinoid, the *n*-propyl analogue of Δ^9 -tetrahydrocannabinol (THC) (Figure 1), which was first detected in cannabis by Gill *et al.* (1970) and named Δ^9 -tetrahydrocannabivarin (THCV) by Merkus (1971). The initial objective of this research was to establish whether THCV can activate or block cannabinoid CB₁ or CB₂ receptors. Some of our experiments

were performed with membranes prepared from healthy brain tissue, which is densely populated with CB₁ but not CB₂ receptors (reviewed in Howlett *et al.*, 2002), or from Chinese hamster ovary (CHO) cells transfected with hCB₂ receptors. These membranes were used to investigate the ability of THCV to displace [³H]CP55940 from CB₁- and CB₂-binding sites and to determine whether it behaves as a CB₁ or CB₂ receptor agonist or antagonist. Experiments were also carried out with the mouse isolated vas deferens, a tissue in which cannabinoid receptor agonists such as *R*-(+)-WIN55212, CP55940, THC and 2-arachidonoyl ethanolamide (anandamide) can inhibit electrically evoked contractions (Devane *et al.*, 1992; Pertwee

*Author for correspondence; E-mail: rgp@abdn.ac.uk




Figure 1 Structures of THC and THCV.

et al., 1995b). This they are thought to do by acting on prejunctional neuronal cannabinoid CB₁ receptors to inhibit release of the contractile neurotransmitters, ATP, acting on postjunctional P2X purinoceptors, and noradrenaline, acting on postjunctional α_1 -adrenoceptors (von Kügelgen & Starke, 1991; Trendelenburg *et al.*, 2000; see also Pertwee, 1997; Schlicker & Kathman, 2001). Experiments were also performed with (–)-7-hydroxy-cannabidiol-dimethylheptyl, a synthetic analogue of the phytocannabinoid, (–)-cannabidiol, that inhibits electrically evoked contractions of the mouse vas deferens through a mechanism that appears to operate prejunctionally and to be at least partly CB₁ receptor-independent (Pertwee *et al.*, 2005). Some of the results described in this paper have been presented to the British Pharmacological Society (Pertwee *et al.*, 2004).

Methods

The methods used comply with the U.K. Animals (Scientific Procedures) Act, 1986 and Associated Guidelines for the Use of Experimental Animals.

Drugs and chemicals

THCV was supplied by GW Pharmaceuticals (Porton Down, Wiltshire, U.K.), THC by the National Institute on Drug Abuse (Bethesda, MD, U.S.A.) and (–)-7-hydroxy-cannabidiol-dimethylheptyl by Professor R. Mechoulam (Hebrew University of Jerusalem, Israel). SR141716A and SR144528 were obtained from Sanofi-Aventis (Montpellier, France). Phenylephrine hydrochloride, β,γ -methyleneadenosine 5'-triphosphate (β,γ -methylene-ATP), anandamide and clonidine hydrochloride were purchased from Sigma-Aldrich (Poole, Dorset, U.K.), *R*-(+)-WIN55212 and CP55940 from Tocris

(Bristol, U.K.) and capsaicin from Research Biochemicals International (Natick, MA, U.S.A.). Phenylephrine hydrochloride, β,γ -methylene-ATP and clonidine were dissolved in a 0.9% aqueous solution of NaCl (saline). *R*-(+)-WIN55212 was dissolved in a 50% (v/v⁻¹) solution of dimethyl sulphoxide (DMSO) in saline and all other drugs were dissolved in pure DMSO. Drugs were added to organ baths in a volume of 10 μ l. For the binding experiments, [³H]CP55940 (168 Ci mmol⁻¹), [³H]*R*-(+)-WIN55212 (40 Ci mmol⁻¹) and [³⁵S]GTP γ S (1250 Ci mmol⁻¹) were obtained from Perkin-Elmer Life Sciences Inc. (Boston, MA, U.S.A.). [³H]SR141716A (44 Ci mmol⁻¹) was obtained from Amersham Biosciences U.K. Ltd (Little Chalfont, Buckinghamshire, U.K.), GTP γ S and adenosine deaminase from Roche Diagnostic (Indianapolis, IN, U.S.A.) and GDP from Sigma-Aldrich.

CHO cells

CHO cells stably transfected with cDNA encoding human cannabinoid CB₂ receptors (B_{max} = 72.6 pmol mg⁻¹ protein) were maintained at 37°C and 5% CO₂ in Dulbecco's Modified Eagles's medium (DMEM) nutrient mixture F-12 HAM supplemented with 2 mM L-glutamine, 10% foetal calf serum, 0.6% penicillin–streptomycin, hygromycin B (300 μ g ml⁻¹) and G 418 (600 μ g ml⁻¹). These CHO-hCB₂ cells were passed twice a week using a nonenzymatic cell dissociation solution.

Membrane preparation

Binding assays with [³H]CP55940 and with [³⁵S]GTP γ S were performed with mouse whole brain membranes, prepared as described by Thomas *et al.* (2004), or with CHO-hCB₂ cell membranes (Ross *et al.*, 1999a). The hCB₂ transfected cells were removed from flasks by scraping and then frozen as a pellet at –20°C until required. Before use in a radioligand-binding assay, cells were defrosted, diluted in 50 mM Tris-binding buffer (radioligand displacement assay) or GTP γ S-binding buffer ([³⁵S]GTP γ S-binding assay), and homogenized with a 1 ml hand-held homogenizer. Protein assays were performed using a Bio-Rad Dc kit (Bio-Rad, Hercules, CA, U.S.A.).

Radioligand displacement assay

The assays were carried out with [³H]CP55940, Tris-binding buffer (50 mM Tris-HCl; 50 mM Tris-Base; 0.1% BSA), total assay volume 500 μ l, using the filtration procedure described previously by Ross *et al.* (1999b). Binding was initiated by the addition of either the brain membranes (33 μ g protein per well) or the transfected hCB₂ cells (25 μ g protein per well). All assays were performed at 37°C for 60 min before termination by addition of ice-cold Tris-binding buffer and vacuum filtration using a 24-well sampling manifold (cell harvester; Brandel Inc., Gaithersburg, MD, U.S.A.) and GF/B filters (Whatman, Maidstone, U.K.) that had been soaked in wash buffer at 4°C for at least 24 h. Each reaction well was washed six times with a 1.2 ml aliquot of Tris-binding buffer. The filters were oven-dried for 60 min and then placed in 5 ml of scintillation fluid (Ultima Gold XR, Packard). Radioactivity was quantified by liquid scintillation spectrometry. Specific binding was defined as the difference between the binding that occurred in the presence and absence of 1 μ M unlabelled CP55940. The

concentration of [^{3} H]CP55940 used in our displacement assays was 0.7 nM. THCV was stored as a stock solution of 10 mM in DMSO, the vehicle concentration in all assay wells being 0.1% DMSO. The binding parameters for [^{3} H]CP55940, determined by fitting data from saturation-binding experiments to a one-site saturation plot using GraphPad Prism, were 2336 fmol mg⁻¹ protein (B_{max}) and 2.31 nM (K_d) in mouse brain membranes (Thomas *et al.*, 2004), and 72570 fmol mg⁻¹ protein (B_{max}) and 1.043 nM (K_d) in hCB₂-transfected cells.

[^{35} S]GTP γ S-binding assay

The method for measuring agonist-stimulated [^{35} S]GTP γ S binding to cannabinoid CB₁ receptors was adapted from the methods of Kurkinen *et al.* (1997) and Breivogel *et al.* (2001). The conditions used for measuring agonist-stimulated [^{35} S]GTP γ S binding to transfected cannabinoid CB₂ receptors were adapted from those used by MacLennan *et al.* (1998) and Griffin *et al.* (1999). The assays were carried out with GTP γ S-binding buffer (50 mM Tris-HCl; 50 mM Tris-Base; 5 mM MgCl₂; 1 mM EDTA; 100 mM NaCl; 1 mM dithiothreitol; 0.1% BSA) in the presence of [^{35} S]GTP γ S and GDP, in a final volume of 500 μ l. Binding was initiated by the addition of [^{35} S]GTP γ S to the wells. Nonspecific binding was measured in the presence of 30 μ M GTP γ S. The drugs were incubated in the assay for 60 min at 30°C. The reaction was terminated by a rapid vacuum filtration method using Tris-binding buffer as described previously, and the radioactivity was quantified by liquid scintillation spectrometry. The concentrations of [^{35} S]GTP γ S and GDP present in the assay varied depending on whether the assay was conducted with mouse brain or transfected cell membranes. However, the protein concentration was the same in all the [^{35} S]GTP γ S-binding assays (5 μ g protein per well). When the assay was conducted with mouse brain membranes, 0.1 nM [^{35} S]GTP γ S and 30 μ M GDP were present, whereas the corresponding concentrations present when the assay was conducted with transfected cell membranes were 0.7 nM and 320 μ M, respectively. Additionally, mouse brain membranes were preincubated for 30 min at 30°C with 0.5 U ml⁻¹ adenosine deaminase (200 U mg⁻¹) to remove endogenous adenosine. Agonists and antagonists were stored as a stock solution of 1 or 10 mM in DMSO, the vehicle concentration in all assay wells being 0.11% DMSO.

Vas deferens experiments

Vasa deferentia were obtained from albino MFI mice weighing 31–59 g. The tissues were mounted vertically in 4 ml organ baths. They were then subjected to electrical stimulation of progressively greater intensity, followed by an equilibration procedure in which they were exposed to alternate periods of stimulation (2 min) and rest (10 min) until contractions with consistent amplitudes were obtained (Thomas *et al.*, 2004). These contractions were monophasic and isometric, and were evoked by 0.5 s trains of pulses of 110% maximal voltage (train frequency 0.1 Hz; pulse frequency 5 Hz; pulse duration 0.5 ms).

Except in our experiments with phenylephrine, all drug additions were made to the organ baths after the equilibration period and there was no washout between these additions. In most experiments, there was an initial application of a potential antagonist or its vehicle. This was followed 28 min

later by a 2-min period of electrical stimulation, at the end of which the lowest of a series of concentrations of the twitch inhibitors, *R*-(+)-WIN55212, CP55940, THC, anandamide, (-)-7-hydroxy-cannabidiol-dimethylheptyl or clonidine, was applied. After a period of rest, the tissues were electrically stimulated for 2 min and then subjected to a further addition of twitch inhibitor. This cycle of drug addition, rest and 2 min stimulation was repeated so as to construct cumulative concentration–response curves. Only one concentration–response curve was constructed per tissue (Pertwee *et al.*, 1996). Rest periods were 3 min for clonidine, 13 min for *R*-(+)-WIN55212, CP55940 and anandamide, 28 min for THC and THCV, and 58 min for (-)-7-hydroxy-cannabidiol-dimethylheptyl. Experiments were also performed with capsaicin. This drug was added at intervals of 3 min and the tissues were not rested from electrical stimulation between these additions. In some experiments, cumulative concentration–response curves for THCV were constructed without prior addition of any other compound, again using a cycle of drug addition, 28 min rest and 2 min stimulation.

In experiments with β , γ -methylene-ATP, no electrical stimuli were applied after the equilibration procedure. Log concentration–response curves of β , γ -methylene-ATP were constructed cumulatively without washout. THCV, WIN or drug vehicle was added 30 min before the first addition of β , γ -methylene-ATP, each subsequent addition of which was made immediately after the effect of the previous dose had reached a plateau (dose cycles of 1–2 min). Only one addition of phenylephrine was made to each tissue and this was carried out 30 min after the addition of THCV, WIN or drug vehicle.

Analysis of data

Values have been expressed as means and variability as s.e.m. or as 95% confidence limits. The concentration of THCV that produced a 50% displacement of radioligand from specific binding sites (IC_{50} value) was calculated using GraphPad Prism 4. Its dissociation constant (K_i -value) was calculated using the equation of Cheng & Prusoff (1973). Net agonist-stimulated [^{35} S]GTP γ S-binding values were calculated by subtracting basal binding values (obtained in the absence of agonist) from agonist-stimulated values (obtained in the presence of agonist) as detailed elsewhere (Ross *et al.*, 1999a). Inhibition of the electrically evoked twitch response of the vas deferens has been expressed in percentage terms, and this has been calculated by comparing the amplitude of the twitch response after each addition of a twitch inhibitor with its amplitude immediately before the first addition of the inhibitor. Contractile responses to phenylephrine and β , γ -methylene-ATP have been expressed as increases in tension (g).

Values for EC_{50} , maximal effect (E_{max}) and the s.e.m. or 95% confidence limits of these values have been calculated by nonlinear regression analysis using the equation for a sigmoid concentration–response curve (GraphPad Prism). The apparent dissociation constant (K_B) values for antagonism of agonists by THCV in the vas deferens or [^{35} S]GTP γ S-binding assay have been calculated by Schild analysis from the concentration ratio, defined as the concentration of an agonist that elicits a response of a particular size in the presence of a competitive reversible antagonist at a concentration, B , divided by the concentration of the same agonist that produces an identical response in the absence of the antagonist. The

methods used to determine the concentration ratio and apparent K_B -values and to establish whether log concentration–response plots deviated significantly from parallelism are detailed elsewhere (Pertwee *et al.*, 2002). Mean values have been compared using Student's two-tailed *t*-test for unpaired data or one-way analysis of variance (ANOVA) followed by Dunnett's test (GraphPad Prism). A *P*-value <0.05 was considered to be significant.

Results

Radioligand experiments

THCV displaced [^{3} H]CP55940 from specific binding sites in mouse brain and CHO-hCB₂ cell membranes in a manner that fitted significantly better to a one-site than a two-site competition curve (*P* < 0.05; GraphPad Prism 4). Its mean K_i -values were 75.4 and 62.8 nM, respectively (Figure 2). THCV also displaced [^{3} H]*R*-(+)-WIN55212 and [^{3} H]SR141716A from specific binding sites in mouse brain membranes, its mean EC_{50} values with 95% confidence limits shown in brackets being 61.3 nM (48.6 and 77.3 nM; *n* = 4–7) and 86.8 nM (63.8 and 118.1 nM; *n* = 4–6), respectively. The corresponding EC_{50} value of THCV for displacement of [^{3} H]CP55940 is 98.2 nM (69.6 and 138.6 nM; *n* = 4–8).

The ability of CP55940 to stimulate [^{35} S]GTP γ S binding to mouse brain and CHO-hCB₂ membranes was attenuated by THCV, which at 1 μ M produced significant dextral shifts in the log concentration–response curves of this cannabinoid receptor agonist that did not deviate significantly from parallelism (Figure 3). The mean apparent K_B -values for this antagonism are shown in Table 1, as are the mean apparent K_B -values of SR141716A for antagonism of CP55940 in mouse brain membranes and of SR144528 for antagonism of CP55940 in the CHO-hCB₂ cell membranes. At 1 μ M, THCV also produced a significant parallel dextral shift in the log concentration–response curve of *R*-(+)-WIN55212 for stimulation of GTP γ S binding to mouse brain membranes (see Table 1 for its apparent K_B -value against *R*-(+)-WIN55212).

Micromolar concentrations of THCV inhibit evoked contractions of the vas deferens

THCV produced a concentration-related inhibition of electrically evoked contractions of the mouse isolated vas deferens with an EC_{50} of 12.7 μ M (6.9 and 23.2 μ M) (Figure 4). It is unlikely that this effect was CB₁-receptor mediated as it was not attenuated by SR141716A at 100 nM (*n* = 7; data not

shown), a concentration that equals or exceeds concentrations of this CB₁-selective antagonist found previously to antagonize established CB₁ receptor agonists in the same bioassay (Pertwee *et al.*, 1995b; Ross *et al.*, 2001). At 32 μ M, a concentration at which it produced a marked inhibition of




Figure 2 Displacement of [^{3} H]CP55940 by THCV from specific binding sites in (a) mouse whole brain membranes and (b) CHO-hCB₂ cell membranes. Each symbol represents the mean percent displacement $\pm$ s.e.m. Mean K_i -values for this displacement with 95% confidence limits shown in brackets were calculated by the Cheng–Prusoff equation to be (a) 75.4 nM (53.4 and 106.3 nM; *n* = 4–8) in mouse whole brain membranes and (b) 62.8 nM (52.5 and 75.3 nM; *n* = 6) in CHO-hCB₂ cell membranes.




Figure 3 The effect of 1 μ M THCV on the mean log concentration–response curve of CP55940 for stimulation of [^{35} S]GTP γ S binding (a) to mouse whole brain membranes and (b) to CHO-hCB₂ cell membranes. Each symbol represents the mean percentage increase in [^{35} S]GTP γ S binding $\pm$ s.e.m. (*n* = 6). Mean apparent K_B -values of THCV for its antagonism of CP55940 have been calculated from these data and these values are listed in Table 1.

Table 1 Mean apparent K_B -values of THCV, SR141716A and SR144528 for antagonism of CP55940- or *R*-(+)-WIN55212-induced activation of [^{35} S]GTP γ S binding to mouse whole brain or CHO-hCB₂ membranes

Antagonist	Agonist	Membrane preparation	Mean apparent K_B (nM)	95% confidence limits (nM)	<i>n</i>
THCV (1000 nM)	CP55940	Brain	93.1	66.5 and 130.6	6
THCV (1000 nM)	<i>R</i> -(+)-WIN55212	Brain	85.4	29.3 and 270.5	5
SR141716A (10 nM)	CP55940	Brain	0.09	0.021 and 0.41	4
THCV (1000 nM)	CP55940	CHO-hCB ₂	10.1	5.0 and 20.5	6
SR144528 (100 nM)	CP55940	CHO-hCB ₂	0.49	0.26 and 0.85	6

Mean apparent K_B -values were calculated by Schild analysis using data obtained with the antagonist concentrations shown.




Figure 4 The mean log concentration–response curve of THC in the mouse isolated vas deferens. Each symbol represents the mean value $\pm$ s.e.m. for inhibition of electrically evoked contractions expressed as a percentage of the amplitude of the twitch response measured immediately before the first addition to the organ bath of THC. Tissues were exposed to THC concentrations ranging either from 3.2 nM to 10 μ M ($n = 10$) or from 1 to 100 μ M ($n = 10$).

electrically evoked contractions, THC also attenuated contractile responses of the vas deferens to both the P2 receptor agonist β , γ -methylene-ATP, and the α_1 -adrenoceptor agonist, phenylephrine hydrochloride (Figure 5). In contrast, at 1 μ M, a concentration at which it had no detectable inhibitory effect on electrically evoked contractions (Figure 4), THC did not induce any significant reduction in the amplitude of contractions induced either by β , γ -methylene-ATP ($n = 8$; data not shown) or by phenylephrine (Figure 5). These findings suggest that THC inhibited electrically evoked contractions of the vas deferens, at least in part, by acting postjunctionally to block contractile responses to endogenously released ATP and noradrenaline.

THCV behaves as a potent surmountable competitive antagonist of R-(+)-WIN55212 in the vas deferens

As shown in Figure 6, at concentrations well below those at which it inhibited electrically evoked contractions, THC opposed R-(+)-WIN55212-induced inhibition of the twitch response in a manner that was concentration-related and not accompanied by any significant change in the maximum effect ($E_{\max}$) of R-(+)-WIN55212 ($P > 0.05$; ANOVA followed by Dunnett's test; $n = 6$ –9). The dextral shifts produced by THC in the log concentration–response curve of R-(+)-WIN55212 do not deviate significantly from parallelism and yield a Schild plot with a slope that is not significantly different from unity (Figure 6). The mean apparent K_B -value of THC was calculated by the Tallarida method (see Pertwee *et al.*, 2002) to be 1.5 nM (Table 2). At 1 μ M, a concentration that markedly attenuated electrically evoked contractions (Figure 6), R-(+)-WIN55212 did not decrease the ability of β , γ -methylene-ATP ($n = 7$ or 10; data not shown) or phenylephrine (Figure 5) to induce contractions of the vas deferens.

THCV is also a potent surmountable competitive antagonist of anandamide, methanandamide and CP55940 in the vas deferens

THCV was shown to antagonize anandamide at 10, 100 and 1000 nM (Figure 7), and methanandamide and CP55940 at 100 nM (Table 2). The dextral shifts produced by THC in the log concentration–response curves of these twitch inhibitors did not deviate significantly from parallelism. The mean apparent K_B -value for the antagonism of anandamide by 10 nM THC with its 95% confidence limits shown in brackets is 1.4 nM (0.36 and 7.50 nM). Mean apparent K_B -values for antagonism of anandamide, methanandamide and CP55940 by 100 nM THC are listed in Table 2.

THCV (100 nM) does not antagonize clonidine, capsaicin, (–)-7-hydroxy-cannabidiol-dimethylheptyl or THC in the vas deferens

At 100 nM, THC did not reduce the ability of clonidine, capsaicin or (–)-7-hydroxy-cannabidiol-dimethylheptyl to inhibit electrically evoked contractions (Figure 7 and Table 2), indicating it to possess at least some degree of selectivity as an antagonist of twitch inhibitors in the vas deferens. Nor did 100 nM THC antagonize the cannabinoid receptor agonist, THC ($n = 11$; data not shown). However, at 1 μ M, THC did produce a significant dextral shift in the log concentration–response curve of THC that did not deviate significantly from parallelism (see Table 2 for its apparent K_B -value against THC).

Discussion

Well-established mixed CB₁/CB₂ cannabinoid receptor ligands such as CP55940, R-(+)-WIN55212 and THC displace [³H]CP55940 from specific binding sites on membranes prepared from brain tissue or from cells transfected with CB₂ receptors (reviewed in Pertwee, 1997; Howlett *et al.*, 2002), and THC was found to share this ability. The K_i -value of THC determined from our experiments with mouse brain membranes (75.4 nM) presumably represents its K_i for the mouse CB₁ receptor, as there is little evidence for the presence of a significant population of CB₂ receptors in healthy brain tissue (reviewed in Howlett *et al.*, 2002). This K_i -value is at least 1.8 times greater than reported CB₁ K_i -values of its structural analogue, THC, determined in experiments with [³H]CP55940 using rat brain membranes (1.6–43 nM; see Pertwee, 1997). However, the hCB₂ K_i -value of THC (62.8 nM) is little different from hCB₂ K_i -values of THC determined previously with [³H]CP55940 (reviewed in Pertwee, 1997).

THCV behaved as a reasonably potent competitive antagonist of CP55940, as indicated by the manner in which it antagonized the ability of this cannabinoid receptor agonist to stimulate [³⁵S]GTP γ S binding in experiments with mouse brain membranes (Figure 3). Results from additional [³⁵S]GTP γ S-binding assays conducted with mouse brain membranes indicated that THC also antagonized R-(+)-WIN55212, again in an apparently competitive manner. THC exhibited similar potencies against CP55940 and R-(+)-WIN55212 in these experiments, suggesting that both agonists were competing with THC for the same target. It is likely that this target




Figure 5 Upper panel: the effect of pretreatment with THCv on mean increases in tension of the mouse isolated vas deferens induced by β,γ -methylene ATP in the presence of DMSO ($\circ$) or 32 μ M THCv ($\bullet$). For the construction of log concentration-response curves, β,γ -methylene ATP was first added 30 min after DMSO or THCv ($n=7$ or 8). Lower panels: the effect of pretreatment with R -(+)-WIN55212 or THCv on mean increases in tension of the mouse isolated vas deferens induced by (a) 32 μ M phenylephrine or (b) 3.2 μ M phenylephrine. Additions of phenylephrine were made 30 min after DMSO (open columns), THCv or R -(+)-WIN55212 ($n=8$). In all panels, mean increases in tension are expressed in grams $\pm$ s.e.m. The asterisks indicate significant differences between responses to β,γ -methylene ATP (unpaired t -test) or to phenylephrine (ANOVA followed by Dunnett's test) in the absence of added cannabinoids, and corresponding responses in the presence of R -(+)-WIN55212 or THCv ($*P<0.05$; $***P<0.001$).

was the cannabinoid CB_1 receptor as results from the brain membrane experiments showed that the apparent K_B -value of THCv for its antagonism of CP55940 (Table 1) did not deviate significantly from its corresponding K_I -value for displacement of [^3H]CP55940 (Figure 2).

THCV also behaved as a competitive CB_2 receptor antagonist, as measured by its ability to antagonize CP55940 in the [^3S]GTP γ S-binding assay when CHO-h CB_2 cell membranes were used. Interestingly, its apparent K_B -value in

these experiments was significantly less than its apparent K_B -value for the antagonism of CP55940-induced activation of [^3S]GTP γ S binding in mouse brain membranes (Table 2), indicating it to be more potent as a CB_2 than a CB_1 receptor antagonist. Unexpectedly, its h CB_2 K_B -value was also significantly lesser than its K_I -value for the displacement of [^3H]CP55940 from CHO-h CB_2 cell membranes (Figure 2). Why this should be remains to be established. It is noteworthy, however, that we also found the corresponding h CB_2 K_B -value




Figure 6 Upper panel: the effect of pretreatment with THCv on the mean log concentration–response curve of *R*-(+)-WIN55212 in the mouse isolated vas deferens. Each symbol represents the mean value $\pm$ s.e.m. for inhibition of electrically evoked contractions expressed as a percentage of the amplitude of the twitch response measured immediately before the first addition of *R*-(+)-WIN55212 to the organ bath. THCv or DMSO was added 30 min before the first addition of *R*-(+)-WIN55212, further additions of which were made at 15-min intervals. Each log concentration–response curve was constructed cumulatively without washout ($n=6-9$). Lower panel: Schild plot for antagonism of *R*-(+)-WIN55212 by 10–1000 nM THCv, in which values for $\log x-1$ were calculated from the data shown in the upper panel (x = concentration ratio). The slope of this plot is 0.99 ± 0.14 and this does not differ significantly from unity ($P > 0.05$; one-sample *t*-test). The mean apparent K_B -value of THCv for its antagonism of *R*-(+)-WIN55212 has been calculated from this slope by Schild analysis and is listed in Table 1.

of the established CB_2 -selective antagonist SR144528 (Table 1) to be significantly less than the mean K_i -value of this ligand for its displacement of [^3H]CP55940 from CHO-hCB $_2$ cell membranes. More specifically, we found this K_i -value with its 95% confidence limits shown in brackets to be 7.5 nM (5.7 and 10.0; $n=6-8$), a value that does not deviate significantly from the hCB $_2$ K_i -value of SR144528 determined previously in this laboratory (Ross *et al.*, 1999a). One possibility, that the potency of THCv as a hCB $_2$ receptor antagonist was found to be so much greater than its affinity for hCB $_2$ receptors because THCv binds more readily to these receptors in the presence of GTP γ S-binding buffer (see Methods), is unlikely as we found THCv to be no more potent in displacing [^3H]CP55940 from CHO-hCB $_2$ cell membranes when this was determined using GTP γ S-binding buffer (mean $K_i=68.1$ nM; 95% confidence limits = 44.7 and 103.9 nM; $n=5$ or 6) instead of the Tris-binding buffer used in all our other binding experiments with radiolabelled cannabinoids (Figure 2).

Although THCv behaved as a cannabinoid receptor antagonist in the [^3S]GTP γ S-binding assays, it was found to share the ability of CB_1 receptor agonists to inhibit electrically evoked contractions of the mouse isolated vas deferens (reviewed in Pertwee, 1997). It is likely, however, that the mechanism by which THCv inhibited these contractions is not the same as the mechanism that underlies the inhibition of electrically evoked contractions induced by THC or other established CB_1 receptor agonists. Thus, while CB_1 receptor agonists appear to act on CB_1 receptors located on prejunctional neurones to produce this effect (reviewed in Pertwee 1997; Schlicker & Kathman, 2001), THCv probably acted in a CB_1 -receptor-independent manner as its EC_{50} for twitch inhibition (12.7 μ M) greatly exceeded its K_i for CB_1 -binding sites and as it was not antagonized by the CB_1 -selective antagonist, SR141716A, when this was administered at a concentration (100 nM) found previously to oppose inhibition of electrically evoked contractions of the mouse vas deferens induced by CB_1 receptor agonists (Pertwee *et al.*, 1995b). THCv could well have produced its inhibitory effect on electrically evoked contractions of the vas deferens by acting postjunctionally to oppose the contractile effects of noradrenaline and ATP that were presumably being released in response to electrical stimulation (see Introduction). Thus, the amplitudes of both phenylephrine- and β , γ -methylene-ATP-evoked contractions of this tissue were reduced by THCv when this was administered at a concentration that attenuated electrically evoked contractions of the vas deferens (32 μ M), but not

Table 2 Mean apparent K_B -values of THCv for antagonism of drug-induced inhibition of electrically evoked contractions of the mouse isolated vas deferens

THCV (nM)	Twitch inhibitor	Mean apparent K_B of THCv (nM)	95% confidence limits (nM)	n
10–1000	<i>R</i> -(+)-WIN55212	1.5	1.1 and 2.3	6–9
100	Anandamide	1.2	0.2 and 6.2	7
100	Methanandamide	4.6	1.5 and 11.6	12
100	CP55940	10.3	3.8 and 31.7	14
1000	THC	96.7	15.4 and 978	10
100	Clonidine	> 100	—	8
100	Capsaicin	> 100	—	8
100	7-OH-CBD-DMH	> 100	—	8

7-OH-CBD-DMH, (–)-7-hydroxy-cannabidiol-dimethylheptyl. Mean apparent K_B -values were calculated by Schild analysis using data obtained with the concentrations of THCv shown (see also Figures 6 and 7).




Figure 7 The effect of pretreatment with THCv on the mean log concentration–response curves of anandamide ($n=7$ or 8) and clonidine ($n=8$) in the mouse isolated vas deferens. Each symbol represents the mean value $\pm$ s.e.m. for inhibition of electrically evoked contractions expressed as a percentage of the amplitude of the twitch response measured immediately before the first addition of twitch inhibitor to the organ bath. THCv or DMSO was added 30 min before the first addition of anandamide or clonidine, further additions of which were made at 15- and 5-min intervals, respectively. Each log concentration–response curve was constructed cumulatively without washout.

when it was administered at a concentration that did not affect the amplitude of electrically evoked contractions ($1 \mu\text{M}$). Taken together, our brain membrane and vas deferens data suggest that while THCv has significant affinity for the CB_1 receptor, it lacks detectable CB_1 receptor efficacy. This is in line with the hypothesis that the length of the C-3 side chain of classical cannabinoids such as THC is an important determinant of the affinity or efficacy displayed by these ligands at CB_1 receptors (reviewed in Razdan, 1986; Howlett *et al.*, 2002). Our finding that THCv was less potent than THC as an inhibitor of electrically evoked contractions of the mouse vas deferens (Figure 4; Pertwee *et al.*, 1995b), agrees with an earlier report that THCv shows less activity than THC as an inhibitor of electrically evoked contractions of the guinea-pig isolated ileum (Gill *et al.*, 1970).

At concentrations below those at which it inhibited electrically evoked contractions of the mouse vas deferens, THCv opposed the abilities of the established CB_1 receptor

agonists, R -(+)-WIN55212, anandamide, methanandamide, CP55940 and THC, to inhibit the twitch response. This it did in a competitive, surmountable manner. For R -(+)-WIN55212, at least, it is likely that the interaction with THCv took place on presynaptic neurones rather than postsynaptically, as the amplitudes of β , γ -methylene-ATP- and phenylephrine-evoked contractions of the vas deferens were unaffected by a concentration of R -(+)-WIN55212 that did markedly inhibit electrically evoked contractions of this tissue preparation. THCv produced its antagonism of cannabinoids at concentrations that by themselves did not affect the amplitude of electrically evoked contractions, or indeed [^{35}S]GTP γ S binding to brain or CHO-hCB $_2$ cell membranes (data not shown), suggesting it to be a neutral antagonist (reviewed in Pertwee, 2005a).

At 100 nM, a concentration at which it antagonized R -(+)-WIN55212, anandamide, methanandamide and CP55940 in the vas deferens, THCv produced no antagonism of clonidine or capsaicin. This is an indication that it possesses selectivity and also suggests that, at 100 nM at least, it was not acting against any of the cannabinoids we investigated by blocking α_2 -adrenergic or TRPV1 receptors. Nor did 100 nM THCv antagonize (-)-7-hydroxy-cannabidiol-dimethylheptyl, an analogue of cannabidiol that has been postulated to act at least in part through an as yet unidentified neuronal non- CB_1 target in the vas deferens (Pertwee *et al.*, 2005).

The apparent K_{B} -value of THCv for its antagonism of THC in the vas deferens (Table 2) is close to its cannabinoid CB_1 K_{i} -value (Figure 2) and to its apparent K_{B} -values for antagonism of CP55940- or R -(+)-WIN55212-induced stimulation of [^{35}S]GTP γ S binding to mouse brain membranes. These findings are consistent with the hypothesis that THC and THCv were competing for CB_1 receptors since there is good evidence that it is mainly CB_1 receptors that mediate cannabinoid-induced inhibition of electrically evoked contractions of the mouse vas deferens (reviewed in Howlett *et al.*, 2002). Moreover, reported CB_1 K_{i} -values of the selective CB_1 receptor antagonist, SR141716A (Howlett *et al.*, 2002), also approximate to its apparent K_{B} -value for antagonism of THC in the mouse vas deferens (Pertwee *et al.*, 1995b). In contrast, the apparent K_{B} -values of THCv for antagonism of R -(+)-WIN55212, anandamide, methanandamide and CP55940 were all significantly less than its cannabinoid CB_1 K_{i} -value. In spite of these findings, however, it would be premature to conclude that THCv antagonized these other cannabinoids in a manner that was entirely CB_1 receptor-independent. Thus, firstly the CB_1 selective antagonist, SR141716A, antagonizes R -(+)-WIN55212 in the mouse vas deferens no less potently than it antagonizes THC (Pertwee *et al.*, 1995b), and secondly Schlicker *et al.* (2003) have found that R -(+)-WIN55212 inhibits evoked noradrenaline release in the vasa deferentia obtained from $\text{CB}_1^{+/+}$ mice but not in vasa deferentia from $\text{CB}_1^{-/-}$ mice, suggesting that R -(+)-WIN55212 might not inhibit electrically evoked contractions of mouse vasa deferentia that lack CB_1 receptors. It is also noteworthy that although there is evidence that some central and peripheral neurones express non- CB_1 receptors that can be activated by R -(+)-WIN55212 and/or anandamide (reviewed in Pertwee, 2005b), the available data suggest that these are not targets at which R -(+)-WIN55212, anandamide or CP55940 would be antagonized by THCv. Thus, some of these proposed targets are activated by capsaicin (Ross *et al.*, 2001; Hájos & Freund,

2002) or clonidine (Molderings *et al.*, 2002), while others appear not to be activated by CP55940 (Breivogel *et al.*, 2001; Mang *et al.*, 2001; Zygmunt *et al.*, 2002). Yet, THCV produced no antagonism of clonidine or capsaicin in the vas deferens (see above), and was no less potent in antagonizing CP55940 than anandamide (Table 2).

The apparent K_{H} -value of THCV for its antagonism of CP55940-induced activation of [^{35} S]GTP γ S binding to CHO-hCB $_2$ cell membranes is essentially the same as its apparent K_{H} -value for antagonism of CP55940 in the mouse vas deferens (Tables 1 and 2). This raises the possibility that it is cannabinoid CB $_2$ receptors for which THCV competes with CP55940, and indeed with *R*-(+)-WIN55212, anandamide and methanandamide, in this tissue preparation. However, there are three reasons for rejecting this hypothesis. Firstly, Rinaldi-Carmona *et al.* (1998) found that the apparent K_{H} -value of SR144528 for its antagonism of CP55940 in the mouse vas deferens (501 nM) greatly exceeded its hCB $_2$ K_{H} -value. Secondly, we have found that SR144528 produces no significant antagonism of *R*-(+)-WIN55212 in the vas deferens (data not shown) even when administered at concentrations (0.1 or 1 μ M) well above its apparent K_{H} -value for antagonism of CP55940 in CHO-hCB $_2$ cell membranes. Finally, while another CB $_2$ receptor antagonist, AM630, has been found to resemble THCV in producing an antagonism of cannabinoid receptor agonists in mouse vasa deferentia that is agonist dependent, it differs from THCV in being more potent against THC than against either anandamide or *R*-(+)-WIN55212 (Pertwee *et al.*, 1995a).

In conclusion, we have obtained evidence from competitive binding and GTP γ S-binding experiments with mouse brain and CHO-hCB $_2$ cell membranes that THCV is a competitive

cannabinoid CB $_1$ and CB $_2$ receptor antagonist. In line with this hypothesis, THCV antagonized THC in the mouse isolated vas deferens, in a manner that suggested that it was competing with THC for CB $_1$ receptors. At concentrations in the micromolar range, well above those at which it is capable of antagonizing THC in the vas deferens, THCV exhibited additional pharmacological actions, in this respect resembling the CB $_1$ selective antagonist SR141716A which, at micromolar concentrations, also interacts with non-CB $_1$ targets (reviewed in Pertwee, 2005a). In addition to THC, several other cannabinoids including *R*-(+)-WIN55212 and anandamide were antagonized by THCV in the mouse vas deferens. Unexpectedly however, the potency exhibited by THCV against these other cannabinoids in the vas deferens was far greater than the potency it exhibited as an antagonist of THC in this tissue preparation or indeed as a CB $_1$ receptor antagonist in mouse brain membranes. Clearly, further experiments will be required to establish how THCV produces antagonism of cannabinoids that is both agonist- and tissue-dependent. Given the high potency that THCV exhibited as an antagonist of anandamide in the vas deferens, it will also be important to investigate the ability of this plant cannabinoid to modulate the tonic activity of the endocannabinoid system induced by endogenous release of anandamide or other endocannabinoids. In addition to providing a more complete characterization of this system, data from such experiments may point to the possible clinical applications for THCV or a related compound.

This investigation was supported by grants from GW Pharmaceuticals, the BBSRC and the National Institute on Drug Abuse (DA-9789). We thank Professor Raphael Mechoulam for (-)-7-hydroxy-cannabidiol-dimethylheptyl.

References

- BREIVOGEL, C.S., GRIFFIN, G., DI MARZO, V. & MARTIN, B.R. (2001). Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. *Mol. Pharmacol.*, **60**, 155–163.
- CHENG, Y.-C. & PRUSOFF, W.H. (1973). Relationship between the inhibition constant (K_i) and the concentration of inhibitor which causes 50 percent inhibition (IC_{50}) of an enzymatic reaction. *Biochem. Pharmacol.*, **22**, 3099–3108.
- DEVANE, W.A., HANUS, L., BREUER, A., PERTWEE, R.G., STEVENSON, L.A., GRIFFIN, G., GIBSON, D., MANDELBAUM, A., ETINGER, A. & MECOULAM, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science*, **258**, 1946–1949.
- ELSOHLY, M.A. (2002). Chemical constituents of *Cannabis*. In: *Cannabis and Cannabinoids. Pharmacology, Toxicology and Therapeutic Potential*, ed. Grotenhermen, F. & Russo, E. pp. 27–36. New York: Haworth Press, Inc.
- GILL, E.W., PATON, W.D.M. & PERTWEE, R.G. (1970). Preliminary experiments on the chemistry and pharmacology of cannabis. *Nature*, **228**, 134–136.
- GRIFFIN, G., WRAY, E.J., TAO, Q., MCALLISTER, S.D., RORRER, W.K., AUNG, M.M., MARTIN, B.R. & ABOOD, M.E. (1999). Evaluation of the cannabinoid CB $_2$ receptor-selective antagonist, SR144528: further evidence for cannabinoid CB $_2$ receptor absence in the rat central nervous system. *Eur. J. Pharmacol.*, **377**, 117–125.
- HÁJOS, N. & FREUND, T.F. (2002). Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. *Neuropharmacology*, **43**, 503–510.
- HOWLETT, A.C., BARTH, F., BONNER, T.I., CABRAL, G., CASELLAS, P., DEVANE, W.A., FELDER, C.C., HERKENHAM, M., MACKIE, K., MARTIN, B.R., MECOULAM, R. & PERTWEE, R.G. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. *Pharmacol. Rev.*, **54**, 161–202.
- KURKINEN, K.M.A., KOISTINAHO, J. & LAITINEN, J.T. (1997). [^{35} S]GTP autoradiography allows region-specific detection of muscarinic receptor-dependent G-protein activation in the chick optic tectum. *Brain Res.*, **769**, 21–28.
- MACLENNAN, S.J., REYNEN, P.H., KWAN, J. & BONHAUS, D.W. (1998). Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB $_1$ and CB $_2$ receptors. *Br. J. Pharmacol.*, **124**, 619–622.
- MANG, C.F., ERBELDING, D. & KILBINGER, H. (2001). Differential effects of anandamide on acetylcholine release in the guinea-pig ileum mediated via vanilloid and non-CB $_1$ cannabinoid receptors. *Br. J. Pharmacol.*, **134**, 161–167.
- MERKUS, F.W.H.M. (1971). Cannabivarin and tetrahydrocannabinol, two new constituents of hashish. *Nature*, **232**, 579–580.
- MOLDERINGS, G.J., BÖNISCH, H., HAMMERMANN, R., GÖTHERT, M. & BRÜSS, M. (2002). Noradrenaline release-inhibiting receptors on PC12 cells devoid of α_2 - and CB $_1$ receptors: similarities to presynaptic imidazoline and edg receptors. *Neurochem. Int.*, **40**, 157–167.
- PERTWEE, R., GRIFFIN, G., FERNANDO, S., LI, X., HILL, A. & MAKRIYANNIS, A. (1995a). AM630, a competitive cannabinoid receptor antagonist. *Life Sci.*, **56**, 1949–1955.
- PERTWEE, R.G. (1997). Pharmacology of cannabinoid CB $_1$ and CB $_2$ receptors. *Pharmacol. Ther.*, **74**, 129–180.
- PERTWEE, R.G. (2005a). Inverse agonism and neutral antagonism at cannabinoid CB $_1$ receptors. *Life Sci.*, **76**, 1307–1324.
- PERTWEE, R.G. (2005b). Pharmacological actions of cannabinoids. In: *Cannabinoids. Handbook of Experimental Pharmacology*, ed. Pertwee, R.G., Vol. 168, pp. 1–51. Heidelberg: Springer-Verlag.

- PERTWEE, R.G., FERNANDO, S.R., GRIFFIN, G., RYAN, W., RAZDAN, R.K., COMPTON, D.R. & MARTIN, B.R. (1996). Agonist-antagonist characterization of 6'-cyanohept-2'-yne- Δ^8 -tetrahydrocannabinol in two isolated tissue preparations. *Eur. J. Pharmacol.*, **315**, 195-201.
- PERTWEE, R.G., GRIFFIN, G., LAINTON, J.A.H. & HUFFMAN, J.W. (1995b). Pharmacological characterization of three novel cannabinoid receptor agonists in the mouse isolated vas deferens. *Eur. J. Pharmacol.*, **284**, 241-247.
- PERTWEE, R.G., ROSS, R.A., CRAIB, S.J. & THOMAS, A. (2002). (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. *Eur. J. Pharmacol.*, **456**, 99-106.
- PERTWEE, R.G., STEVENSON, L.A., ROSS, R.A., PRICE, M.R., WEASE, K.N. & THOMAS, A. (2004). The phytocannabinoid, THCV, potently antagonizes WIN55212-2 and anandamide in the mouse isolated vas deferens. *Proc. Br. Pharmacol. Soc.*, at <http://www.pa2online.org/abstractindex.html>.
- PERTWEE, R.G., THOMAS, A., STEVENSON, L.A., MAOR, Y. & MECHOULAM, R. (2005). (-)-7-Hydroxy-4'-dimethylheptyl-cannabidiol activates a non- CB_1 , non- CB_2 , non-TRPV1 target in the mouse vas deferens in a cannabidiol-sensitive manner. *Neuropharmacology*, **48**, 1139-1146.
- RAZDAN, R.K. (1986). Structure-activity relationships in cannabinoids. *Pharmacol. Rev.*, **38**, 75-149.
- RINALDI-CARMONA, M., BARTH, F., MILLAN, J., DEROCQ, J.-M., CASELLAS, P., CONGY, C., OUSTRIC, D., SARRAN, M., BOUABOULA, M., CALANDRA, B., PORTIER, M., SHIRE, D., BRELIÈRE, J.-C. & LE FUR, G. (1998). SR 144528, the first potent and selective antagonist of the CB_2 cannabinoid receptor. *J. Pharmacol. Exp. Ther.*, **284**, 644-650.
- ROSS, R.A., BROCKIE, H.C., STEVENSON, L.A., MURPHY, V.L., TEMPLETON, F., MAKRIYANNIS, A. & PERTWEE, R.G. (1999a). Agonist-inverse agonist characterization at CB_1 and CB_2 cannabinoid receptors of L759633, L759656 and AM630. *Br. J. Pharmacol.*, **126**, 665-672.
- ROSS, R.A., GIBSON, T.M., BROCKIE, H.C., LESLIE, M., PASHMI, G., CRAIB, S.J., DI MARZO, V. & PERTWEE, R.G. (2001). Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. *Br. J. Pharmacol.*, **132**, 631-640.
- ROSS, R.A., GIBSON, T.M., STEVENSON, L.A., SAHA, B., CROCKER, P., RAZDAN, R.K. & PERTWEE, R.G. (1999b). Structural determinants of the partial agonist-inverse agonist properties of 6'-azidohept-2'-yne- Δ^8 -tetrahydrocannabinol at cannabinoid receptors. *Br. J. Pharmacol.*, **128**, 735-743.
- SCHLICKER, E. & KATHMAN, M. (2001). Modulation of transmitter release via presynaptic cannabinoid receptors. *Trends Pharmacol. Sci.*, **22**, 565-572.
- SCHLICKER, E., REDMER, A., WERNER, A. & KATHMAN, M. (2003). Lack of CB_1 receptors increases noradrenaline release in vas deferens without affecting atrial noradrenaline release or cortical acetylcholine release. *Br. J. Pharmacol.*, **140**, 323-328.
- THOMAS, A., ROSS, R.A., SAHA, B., MAHADEVAN, A., RAZDAN, R.K. & PERTWEE, R.G. (2004). 6'-Azidohept-2'-yne-cannabidiol: a potential neutral, competitive cannabinoid CB_1 receptor antagonist. *Eur. J. Pharmacol.*, **487**, 213-221.
- TRENDELENBURG, A.U., COX, S.L., SCHELBI, V., KLEBROFF, W., KHAIRALLAH, L. & STARKE, K. (2000). Modulation of ^3H -noradrenaline release by presynaptic opioid, cannabinoid and bradykinin receptors and β -adrenoceptors in mouse tissues. *Br. J. Pharmacol.*, **130**, 321-330.
- VON KÜGELGEN, I. & STARKE, K. (1991). Noradrenaline-ATP co-transmission in the sympathetic nervous system. *Trends Pharmacol. Sci.*, **12**, 319-324.
- ZYGMUNT, P.M., ANDERSSON, D.A. & HÖGESTÄTT, E.D. (2002). Δ^9 -tetrahydrocannabinol and cannabinol activate capsaicin-sensitive sensory nerves via a CB_1 and CB_2 cannabinoid receptor-independent mechanism. *J. Neurosci.*, **22**, 4720-4727.

(Received August 1, 2005)

Accepted August 10, 2005

Published online 3 October 2005